期刊文献+

GLP—l受体激动剂的胰岛素增敏效应 被引量:2

Effects of GLP-1 receptor agonists on insulin sensitivity
原文传递
导出
摘要 2型糖尿病的发病机制主要涉及胰岛素抵抗和胰岛素分泌缺乏。研究表明,胰高血糖素样肽一1受体激动剂在有效改善胰岛p细胞功能,促进胰岛素分泌的同时,还能够作用于细胞信号转导,促进脂肪细胞分化和葡萄糖摄取,并通过减轻相关炎性反应因子表达,降低体重等,改善胰岛素抵抗,增加胰岛素敏感性。 Insulin resistance and lack of insulin secretion is the main pathogenesis of type 2 diabe- tes. Researches have shown that glucagon-like peptide-1 ( GLP-I ) receptor agonists could effectively improve the function of pancreatic [3 cell, and promote the secretion of insulin. Moreover, GLP-1 receptor agonists could regulate signal transduction,increase adipocytes differentiation and gXucose uptake, decrease expression of inflammation factors, reduce weight and so on. Therefore, it can improve insulin resistance,increase insulin sensitivity
作者 郑仁东 刘超
出处 《国际内分泌代谢杂志》 北大核心 2012年第5期318-320,共3页 International Journal of Endocrinology and Metabolism
关键词 胰高血糖素样肽-1 信号转导 脂肪细胞分化 葡萄糖摄取 炎症 Glucagon-like peptide-1 Signal transduction Adipocyte differentiation Glucose up- take lntlammation
  • 相关文献

参考文献21

  • 1Lund A, Knop FK, Vilsbll T. Emerging GLP-I receptor agonists. Expert Opin Emerg Drugs ,2011 ,16:607-618.
  • 2Sancho V, Trigo MV, Gonzalez N, et al. Effects of glucagon-like peptide-l and exendins on kinase activity, glucose transport and lipid metabolism in adipocytes from normal and type 2 diabetic rats. J Mol Endocrinol,2005 ,35: 27-38.
  • 3Ames L, Gonzalez N, Tomero-Esteban P, et al. Characteristics of GLP-l and exendins action upon glucose transport and metabolism in type 2 diabetic rat skeletal muscle. Int J Mol Med, 2008 , 22: 127-132.
  • 4Fan R, Kang Z, He L, et al. Exendin-4 improves blood glucose control in both young and aging normal non-diabetic mice, possible contribution of beta cell independent effects. PLoS One, 2011,6: e20443.
  • 5Park S, Hong SM, Ahn IS. Exendin -4 and exercise improve hepatic glucose homeostasis by promoting insulin signaling in diabetic rats. Metabolism,2010,59: 123-133.
  • 6Cabou C, Vachoux C, Campistron G, et al. Brain GLP-I signaling regulates femoral artery hlood flow and insulin sensitivity through hypothalamic PKC-S. Diabetes,2011 ,60: 2245-2256.
  • 7Knauf C, Cani PD, Ait-Belgnaoui A, et al. Brain glucagon-like peptide 1 signaling controls the onset of high-fat diet-induced insulin resistance and reduces energy expenditure. Endocrinology , 2008,149: 4768-4777.
  • 8Gao H, Wang X,Zhang Z,et al. GLP-I amplifies insulin signaling by up-regulation of IRbeta, IRS-I and Glut4 in 313-11 adipocytes. Endocrine,2007 ,32: 90-95.
  • 9徐璐,杨玥,黎明,向红丁.胰升血糖素样肽1对3T3-L1前脂肪细胞增殖及分化的影响[J].中国糖尿病杂志,2011,19(9):670-673. 被引量:4
  • 10Vendrell J , El Bekay R, Peral B, et al. Study of the potential association of adipose tissue GLP-l receptor with obesity and insulin resistance. Endocrinology ,2011,152: 4072-4079.

二级参考文献9

  • 1阴津华,黎明,杨莆,吴从愿.人网膜前脂肪细胞原代培养及其生物学特性研究[J].中华医学杂志,2007,87(12):838-841. 被引量:9
  • 2Wilding JP, Hardy K. Glucagon-like peptide-1 analogues for type 2 diabetes. BMJ, 2011, 342:d410.
  • 3Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet, 2009, 374:39-47.
  • 4Velasquez DA, Beiroa D, Vazquez MJ, et al. Central GLP-1 actions on energy metabolism. Vitam Horm, 2010, 841 303-317.
  • 5Suwa A, Kurama T, Shimokawa T. Adipocyte hyperplasia and RMI1 in the treatment of obesity. FEBS J, 2011, 278: 565-569.
  • 6Buteau J. GLP-1 receptor signaling: effects on pancreatic beta-cell proliferation and survival. Diabetes Metab, 2008, 34: S73-S77.
  • 7Sancho V, Trigo MV, Gonzdlez N, et al. Effects of glucagon-like peptide-1 and exendins on kinase activity, glucose transport and lipid metabolism in adipocytes from normal and type-2 diabetic rats. J Mol Endocrinol,2005, 35 : 27-38.
  • 8Villanueva-Penacarrillo ML, Marquez L, Gonzalez N, et al. Effect of GLP-1 on lipid metabolism in human adipocytes. Horm Metab Res, 2001,33: 73-77.
  • 9黎明,阴津华,张葵,吴从愿,邓洁英.原代培养的人网膜前脂肪细胞分化过程中基因表达和脂肪因子分泌的特征[J].中华内分泌代谢杂志,2010,26(1):56-59. 被引量:3

共引文献3

同被引文献18

  • 1中华医学会糖尿病学分会.中国2型糖尿病防治指南(2010年版)[J].中华糖尿病杂志,2012,20(1):81-117.
  • 2Whiting DR, Guariguata L, Weil C, et al. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030 [J] Diabetes Res Clin Pract, 2011, 94 (3) : 311-321.
  • 3Kim MH, Lee MK. The incretins and pancreatic beta- cell: use of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide to cure type 2 diabetes mellitus [J]. Korean Diabetes J, 2010, 34 (1) : 2-9.
  • 4Prigeon RL, Quddusi S, Pety B, et al. Suppression of glucose production by GLP-1 independent of islet hormones: a novel extrapancreatic effect[J]. Am J Physiol Endocrinol Metab, 2003, 285 (4) : 701-707.
  • 5Koizumi M, Doi R, Fujimoto K, et al. Pancreatic epithelial cells can be converted into insulin-producing cells by GLP-1 in conjunction with virus-mediates gene transfer of pdx-1[J]. Surgery, 2005, 138 (2) : 125-133.
  • 6Levy JC, Matthews DR, Hermans MP. Correct homeostasis model assessment (HOMA) evaluation uses the computer program :J:. Diabetes Care, 1998, 21 (12) : 2191-2192.
  • 7Jacobsen LV, Sogaard B, Riis A. Pharmacokinetics and pharmacodynamics of a premixed formulation of soluble and protamine.retarded insulin aspart [J]. Eur J Clin Pharmacol, 2000, 56 (5) : 399-403.
  • 8Knudsen LB, Nielsen PF, Huusfeldt PO, et al. Potent derivatives of glucagon-like peptide-1 with pharmacokineticproperties suitable for once daily administration [J]. J Med Chem, 2000, 43 (9) : 1664-1669.
  • 9Marre M, Shaw J, Brandle M, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU) [J]. Diabet Med, 2009, 26 (3) : 268-278.
  • 10Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study [J]. Diabetes Care, 2009, 32 (1): 84-90.

引证文献2

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部